The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-07), Repligen's share price is $111.73. Repligen's Book Value per Share for the quarter that ended in Dec. 2024 was $35.17. Hence, Repligen's PB Ratio of today is 3.18.
Good Sign:
Repligen Corp stock PB Ratio (=3.18) is close to 5-year low of 3.18.
The historical rank and industry rank for Repligen's PB Ratio or its related term are showing as below:
RGEN'
s PB Ratio Range Over the Past 10 Years
Min: 2.28 Med: 5.43 Max: 12.36
Current: 3.18
During the past 13 years, Repligen's highest PB Ratio was 12.36. The lowest was 2.28. And the median was 5.43.
RGEN's PB Ratio is ranked worse than 68.73% of 790
companies
in the Medical Devices & Instruments industry
Industry Median: 2.045
vs RGEN: 3.18
During the past 12 months, Repligen's average Book Value Per Share Growth Rate was -0.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 30.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Repligen was 68.90% per year. The lowest was -57.30% per year. And the median was 8.10% per year.
Back to Basics: PB Ratio
Repligen PB Ratio Historical Data
The historical data trend for Repligen's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Repligen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen's PB Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's PB Ratio distribution charts can be found below:
* The bar in red indicates where Repligen's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Repligen's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Repligen PB Ratio Related Terms
Thank you for viewing the detailed overview of Repligen's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGEN has been successfully added to your 